Figures computed from official regulatory filings — .
Analysttarget 4 USD (-3%) · consensus 3/5 · 0 buy · 1 hold · 0 sell
Ownershipinsiders 6.48% · institutions 89.13% · short 4.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ORASURE TECHNOLOGIES INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
37 buys168 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Boyd Steven Kyle | Award | $18.6K | SEC |
| Kenny John P.track record | Other | $17.5K | SEC |
| Boyd Steven Kyle | Award | $16.2K | SEC |
| Bertrand John D. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kenny John P.track record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| McMahon Robert W. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gagliano Nancy J | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Boyd Steven Kyle | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Marmora Lelio | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Boyd Steven Kyle | Buy | $74.8K | conv 50Cluster | SEC |
| Boyd Steven Kyle | Buy | $75.5K | conv 53Cluster | SEC |
| Boyd Steven Kyle | Buy | $74.5K | conv 67ClusterFirst in 12mo | SEC |
| Marmora Lelio | Other | $85.8K | Unusual size | SEC |
| Gagliano Nancy J | Other | $64.3K | Unusual size | SEC |
| McMahon Robert W. | Other | $69.1K | SEC |
| Bertrand John D. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Boyd Steven Kyle | Award | $16.3K | SEC |
| Boyd Steven Kyle | Other | $4.4K | SEC |
| EGLINTON MANNER CARRIEtrack record | Buy | $94.6K | conv 19 | SEC |
| McGrath Kenneth J | Buy | $94.6K | conv 22 | SEC |
| Miller Michele Marie | Other | $32.9K | Unusual size | SEC |
| Miller Michele Marie | Other | $12.3K | SEC |
| Miller Michele Marie | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Miller Michele Marie | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| EGLINTON MANNER CARRIEtrack record | Buy | $66.1K | conv 25First in 12mo | SEC |